Question special

Multiple responses by the experts have followed a similar trend in their conclusions based on the results of the 3 recent sepsis trials: “early recognition and treatment of sepsis is the most important thing” and “look early and often” and “increased awareness, early recognition, and increased attentiveness to the patient . . . is important.” The ProMISe Trial showed, as expected, that treatment intensity was higher in the EGDT group. While it was not associated with an increased mortality rate, this increased treatment intensity was “reflected by significantly higher SOFA scores and more days of receiving advanced cardiovascular support.” Why did this occur? How can clinicians be attentive to sepsis identification and treatment yet also be prudent about not overtreating these patients?